These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31159169)

  • 1. Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study.
    Damiani G; Pacifico A; Russo F; Pigatto PDM; Bragazzi NL; Bonifati C; Morrone A; Watad A; Adawi M
    J Clin Med; 2019 May; 8(6):. PubMed ID: 31159169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature.
    Liu LC; Jin XH; Sun C; Xia JX
    Dermatol Ther; 2021 Mar; 34(2):e14825. PubMed ID: 33527631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report.
    Lu X; Wang W
    Clin Cosmet Investig Dermatol; 2023; 16():1977-1981. PubMed ID: 37539023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab.
    Galluzzo M; D'Adamio S; Campione E; Mazzilli S; Bianchi L; Talamonti M
    J Dermatolog Treat; 2018 Sep; ():1-11. PubMed ID: 30256706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
    Chiricozzi A; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani FM; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Panduri S; Piaserico S; Piscitelli L; Prignano F; Ribero S; Valerio J; Torres T
    J Dermatolog Treat; 2020 Aug; 31(5):476-483. PubMed ID: 31557063
    [No Abstract]   [Full Text] [Related]  

  • 8. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
    Warren RB; Halliday A; Graham CN; Gilloteau I; Miles L; McBride D
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2178-2184. PubMed ID: 29846965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
    López Jiménez P; Suárez Pérez J; Herrera Acosta E; Aguilera Arjona J; Mendiola Fernández MV; Bosch García R; Herrera Ceballos E
    Dermatol Ther; 2019 Jul; 32(4):e12937. PubMed ID: 30983098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
    Chiricozzi A; Conti A; Burlando M; Odorici G; Gaiani F; Panduri S; Malagoli P
    Dermatology; 2019; 235(3):213-218. PubMed ID: 30928971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of secukinumab in erythrodermic psoriasis: A single center experience.
    Bhatnagar A; Singh GK; Deshpande SK; Mitra B; Mitra D; Agrawal V; Reddy S; Patil C; Sandhu S
    Med J Armed Forces India; 2023 Dec; 79(Suppl 1):S6-S12. PubMed ID: 38144608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
    Ortiz-Salvador JM; Saneleuterio-Temporal M; Magdaleno-Tapial J; Velasco-Pastor M; Pujol-Marco C; Sahuquillo-Torralba A; Mateu-Puchades A; Pitarch-Bort G; Marí-Ruiz JI; Mataix-Díaz J; Montesinos-Villaescusa E; Miralles-Botella J; García-Fernández L; Martorell-Calatayud A; Belinchón-Romero I; Sánchez-Carazo JL; Pérez-Ferriols A
    J Am Acad Dermatol; 2019 Aug; 81(2):427-432. PubMed ID: 30872150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab.
    Malakouti M; Jacob SE; Anderson NJ
    Clin Cosmet Investig Dermatol; 2016; 9():347-355. PubMed ID: 27785085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
    Megna M; Di Costanzo L; Argenziano G; Balato A; Colasanti P; Cusano F; Galluccio AG; Gambardella A; Lembo S; Mozzillo R; Scotto Di Luzio G; Fabbrocini G; Balato N
    Expert Opin Biol Ther; 2019 Aug; 19(8):855-861. PubMed ID: 31140882
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.